Jul 24, 2008
Alkermes seeks FDA nod for bipolar disorder drug
Cambridge biotech firm Alkermes Inc. reports that its partner, Johnson & Johnson , has asked the U.S. Food and Drug Administration for approval of the two firms' drug, Risperdal/Consta, as a treatment for ...
Comments
Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.
| Topic | Updated | Last By | Comments |
|---|---|---|---|
| Us Fda probing deaths in German study involving... | Fri | gdpawel | 1 |
| FDA staff sees possible J&J psoriasis drug risks | Jul '08 | Barbara | 1 |
| FDA panel gives mixed review of J&J antibiotic | Jul '08 | bbednarz | 1 |
| Alamogordo Police Logs | Jul '08 | Not a Christian | 9 |
| Harvard University Psych Drug Pusher Dr. Bieder... | Jun '08 | What | 2 |
| Johnson & Johnson Profit Exceeds Estimates on S... | Jun '08 | mwernimont | 2 |
| J&J adds cancer warning to diabetic foot gel | Jun '08 | History Buff | 2 |
